Related Experiment Videos
Vogt-Koyanagi-Harada disease.
R W Read1, N A Rao, E T Cunningham
1Department of Ophthalmology, Doheny Eye Institute, Pathology, University of Alabama at Birmingham, Birmingham, 700 18th Street South, EFH 6001 Alabama, USA. rwr@uab.edu
Current Opinion in Ophthalmology
|January 6, 2001
Summary
Vogt-Koyanagi-Harada disease is an autoimmune condition affecting melanocytes, primarily in certain ethnic groups. Early corticosteroid treatment is crucial, but complications can lead to vision loss.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Vogt-Koyanagi-Harada (VKH) disease is an idiopathic, bilateral, granulomatous inflammatory condition with ocular and neurologic manifestations.
- It predominantly affects individuals of Asian, Latino, Native American, and Asian Indian descent, with a higher incidence in women and occurrence across all age groups, including children.
- Current evidence suggests an autoimmune etiology targeting melanocytes, potentially tyrosinase or related proteins.
Purpose of the Study:
- To review the current understanding of Vogt-Koyanagi-Harada disease, focusing on its etiology, diagnosis, and management.
- To highlight the role of autoimmune processes and melanocyte antigens in VKH disease pathogenesis.
- To discuss therapeutic strategies and the impact of complications on visual prognosis.
Main Methods:
- Review of experimental data and clinical findings related to VKH disease.
- Analysis of diagnostic criteria and the utility of advanced imaging techniques.
- Evaluation of treatment protocols, including corticosteroids and steroid-sparing agents.
Main Results:
- The autoimmune basis of VKH disease, likely targeting melanocyte components, is supported by experimental data.
- Clinical diagnosis relies on physical findings; advanced imaging has not significantly improved diagnostic understanding.
- High-dose corticosteroids are the primary treatment, with steroid-sparing agents used for refractory cases.
Conclusions:
- VKH disease is an autoimmune disorder primarily affecting specific ethnic populations and characterized by ocular inflammation.
- Effective management involves prompt corticosteroid therapy, but complications like subretinal fibrosis and choroidal neovascularization pose significant risks to vision.
- Further research into the precise autoimmune targets and long-term management strategies is warranted to improve patient outcomes.